EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy

Jeffrey Aldrich, Madison Canning, Manali Bhave

Clinical Breast Cancer · 2023

DOI: 10.1016/j.clbc.2023.08.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2023. Verfasst von Jeffrey Aldrich und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is an aggressive disease with a poor prognosis that disproportionately affects young women and African Americans, and represents a major unmet need in the field. TNBCs display a more aggressive growth pattern with an increased risk of advanced disease and high recurrence risk in patients with early stage TNBC. The addition of immunotherapy to chemotherapy for the treatment of patients with early stage TNBC in the (neo) adjuvant setting per the pivotal KEYNOTE 522 significantly improved pCR rates. Despite this advancement, however, approximately 35% of patients had residual disease at the time of surgery and reduced event free survival. Further techniques to assess for molecular residual disease after completion of neoadjuvant chemotherapy (NAC) may allow us to identify patients at high risk of relapse who may benefit from salvage adjuvant systemic therapy, while also potentially de-escalating treatment in those achieving a molecular complete response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBreast NeoplasmsHumansFemaleNeoadjuvant TherapyNeoplasm Recurrence, LocalProgression-Free SurvivalAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Clinical trialsImmunotherapyNeoadjuvant therapyTNBCctDNA

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
  • Department of Medicine, Emory School of Medicine, Emory University, Atlanta, GA.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: manali.ajay.bhave@emory.edu.

Zitieren

APA

Aldrich, J., Canning, M., & Bhave, M. (2023). Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.08.001

Vancouver

Aldrich J, Canning M, Bhave M. Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy. Clinical Breast Cancer. 2023. doi:10.1016/j.clbc.2023.08.001

BibTeX
@article{Aldrich2023,
  author = {Aldrich, Jeffrey and Canning, Madison and Bhave, Manali},
  title = {Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy},
  journal = {Clinical Breast Cancer},
  year = {2023},
  doi = {10.1016/j.clbc.2023.08.001}
}
Kostenlos starten →